Radiotracer breast cancer imaging: Beyond FDG and MIBI

Physica Medica

Volumn 21, Issue SUPPL. 1, 2006, Pages 12-16

  Mankoff, David A ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Division of Nuclear Medicine   (United States)

Author keywords

Breast cancer; PET; Radiotracer imaging; Targeted imaging

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ANNEXIN 5 TECHNETIUM TC 99M; BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; FLUOROESTRADIOL BETA17 F 18; FLUOROTHYMIDINE F 18; FULVESTRANT; GEFITINIB; LETROZOLE; MEDRONATE TECHNETIUM TC 99M; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; TAMOXIFEN; TECHNETIUM SULFUR COLLOID TC 99M; THYMIDINE C 11; TRACER; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANGIOGENESIS; BLOOD FLOW; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CONFERENCE PAPER; ENERGY METABOLISM; HUMAN; IMAGE ANALYSIS; IMAGING SYSTEM; LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; QUANTITATIVE ANALYSIS; RADIATION DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

EID: 34247254856     PISSN: 11201797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1120-1797(06)80016-5     Document Type: Conference Paper

References (54)

1. Taillefer R. The role of 99mTc-sestaMIBI and other conventional radiopharmaceuticals in breast cancer diagnosis. Semin Nucl Med 199: 29; 16-40.
2. Albertini J, Lyman G, Cox C et alii. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996: 276; 1818-1822.
3. Eubank W, Mankoff D. Current and future uses of PET in breast cancer imaging. Semm Nucl Med 2004: 34; 224-240.
4. Eubank W, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G, Lindsley S, Austin-Seymour M, Livingston R. Impact of [F-18]-Fluorodeoxyglucose PET on defining the extent of disease and management of patients with recurrent or metastatic breast cancer. AJR Am J Roentgen 2004: 183; 479-486.
5. Kaklamani V, O'Regan R M. New targeted therapies in breast cancer. Semin Oncol 2004: 31; 20-25.
6. Katzenellenbogen J A, Welch M J, Dehdashti, F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res 1997: 17; 1573-1576.
7. Mankoff D A, Dehdashti F, Shields A F. Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia 2000: 2; 71-88.
8. Gonzalez Trotter D E, Manjeshwar R M, Doss M, Shaller C, Robinson M K, Tandon R, Adams G P, Adler L P. Quantitation of small-animal (124)I activity distributions using a clinical PET/CT scanner. J Nucl Med 2004: 45; 1237-1244.
9. Buck A K, Schirrmeister H, Mattfeldt T, Reske S N. Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging 2004: 31 (Suppl 1); S80-87.
10. Mankoff D A, Dunnwald L K, Gralow J R, Ellis G K, Charlop A, Lawton T J, Schubert E K, Tseng J, Livingston R B. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002: 43; 500-509.
11. Wilson C B J H, Lammertsma A A, McKenzie C G, Sikora K, Jones T. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: A rapid and non-invasive dynamic method. Cancer Research 1992: 52; 1592-1597.
12. Zasadny K R, Tatsumi M, Wahl R L. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging 2003: 30; 274-280.
13. Haubner R, Wester H J, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman S L, Kessler H, Schwaiger M. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001: 42; 326-336.
14. Chen X, Park R, Tohme M, Shahinian A H, Bading J R, Conti P S. Micro PET and autoradiographic imaging of breast cancer alpha V-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem 2004: 15; 41-49.
15. Zheng Q H, Fei X, Liu X, Wang J Q, Bin Sun H, Mock B H, Lee Stone K, Martinez T D, Miller K D, Sledge G W, Hutchins G D. Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-cgs 27023A analogs, new potential PET breast cancer imaging agents. Nucl Med Biol 2002: 29; 761-770.
16. Jagoda E M, Aloj L, Seidel J, Lang L, Moody T W, Green S, Caraco C, Daube-Witherspoon M, Green M V, Eckelman W C. Comparison of an 18F labeled derivative of vasoactive intestinal peptide and 2-deoxy-2-[18F]fluoro-D-glucose in nude mice bearing breast cancer xenografts. Mol Imaging Biol 2002: 4; 369-379.
17. Berger F, Gambhir S S. Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide technologies in living subjects: applications to breast cancer. Breast Cancer Res 2001: 3; 28-35.
18. Sledge G J, McGuire W. Steroid hormone receptors in human breast cancer. Adv Cancer Res 1983: 38; 61-75.
19. Kiesewetter D O, Kilbourn M R, Landvatter S W, Heiman D F, Katzenellenbogen J A, Welch M J. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissue of immature rats. J Nucl Med 1984: 25; 1212-1221.
20. Inoue T, Kim E E, Wallace S, Yang D J, Wong F.C, Bassa P, Cherif A, Delpassand E, Buzdar A, Podoloff D A. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm 1996: 11; 235-245.
21. Seimbille, Y, Benard, F, Rousseau, J, Pepin, E, Aliaga, A, Tessier, G, and van Lier, J E Impact on estrogen receptor binding and target tissue uptake of [18F]fluorine substitution at the 16alpha-position of fulvestrant (faslodex; ICI 182,780). Nucl Med Biol, 31: 691-698, 2004.
22. Brust P, Rodig H, Romer J, Kasch H, Bergmann R, Fuchtner F, Zips D, Baumann M, Steinbach J, Johannsen B. Distribution of 16alpha-[18F]fluoro- estradiol-3,17beta-disulfamate in rats, tumour-bearing mice and piglets. Appl Radiat Isot 2002: 57; 687-695.
23. Mintun M A, Welch M J, Siegel B A, Mathias C J, Brodackj W, McGuire A H, Katzenellenbogen J A. Breast cancer: PET imaging of estrogen receptors. Radiology 1988: 169; 45-48.
24. 18F]fluro-17β-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991: 32; 1526-1531.
25. Mankoff D A, Peterson L M, Tewson T J, Link J M, Gralow J R, Graham M M, Krohn, K A [18F]fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 2001: 42; 679-684.
26. Dehdashti F, Mortimer J E, Siegel B A, Griffeth L K, Bonasera T J, Fusselman M J, Detert D D, Cutler P D, Katzenellenbogen J A, Welch M J. Positron tomographic assessment of estrogen receptors in breast cancer: a comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995: 36; 1766-1774.
27. Campbell F C, Elston C W, Blamey R W, Morris A H, Nicholson R I, Griffeths K, Haybittle J L. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet 1981: 1; 1317-1319.
28. Mortimer J E, Dehdashti F, Siegel B A, Trinkaus K, Katzenellenbogen J A, Welch M J. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001: 19; 2797-2803.
29. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N, Smith I. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001: 61; 8452-8458.
30. Kaye S B. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr Opin Oncol 1998: 10 (Suppl 1); S15-19.
31. Dolan M E, Pegg, A E. 06-benzylguanine and its role in chemotherapy. Clin Cancer Res 1997: 3; 837-847.
32. Sutherland R. Tumor hypoxia and gene expression. Acta Oncologica 1998: 37; 567-574.
33. Hendrikse N H, de Vries E G, Eriks-Fluks L, van der Graaf W T, Hospers G A, Willemsen A T, Vaalburg W, Franssen E J. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res 1999: 59; 2411-2416.
34. Rasey J S, Koh W, Grierson J R, Grunbaum Z, Krohn K A. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiation Oncol Biol Phys 1989: 17; 985-992.
35. Zheng Q H, Liu X, Fei X, Wang J Q, Ohannesian D W, Erickson L C, Stone K L, Hutchins G D. Synthesis and preliminary biological evaluation of radiolabeled O6-benzylguanine derivatives, new potential PET imaging agents for the DNA repair protein O6-alkylguanine-DNA alkyltransferase in breast cancer. Nucl Med Biol 2003: 30; 405-415.
36. Aboagye E O, Price P M. Use of positron emission tomography in anticancer drug development. Invest New Drugs 2003: 21; 169-181.
37. Rajendran J G, Mankoff D A, O'Sullivan F, Peterson L M, Schwartz D L, Conrad E U, Spence A M, Muzi M, Farwell D G, Krohn K A. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004: 10; 2245-2252.
38. Dehdashti F, Grigsby P W, Mintun M A, Lewis J S, Siegel B A, Welch M J. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-atsm: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 2003: 55; 1233-1238.
39. Piwnica-Worms D, Chiu M L, Budding M, Kronauge J F, Kramer R A, Croop J M. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Research 1993: 53; 977-984.
40. Ciarmiello A, Vecchio S D, Silvestro P, Potenta M, Carriero M, Thomas R, Botti G, D'Aiuto G, Salvatore M. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998: 16; 1677-1683.
41. Del Vecchio S, Ciarmiello A, Salvatore M. Clinical imaging of multidrug resistance in cancer. Q J Nucl Med 1999: 43; 125-131.
42. Mankoff D A, Dunnwald L K, Gralow J R, Ellis G K, Schubert E K, Charlop A W, Tseng, J, Rinn K J, Livingston R B. [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow. Nucl Med Biol 2002: 29; 719-727.
43. Muzi M, Link J M, Mankoff D A, Collier A C, Yang X, Unadkat J D. Quantitative estimation of P-glycoprotein transport using [C-11]-verapamil. J Nucl Med 2003: 44; 365R
44. 18F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000: 18; 1689-1695.
45. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000: 18; 1676-1688.
46. Tannock I F. Cell proliferation. In: The Basic Science of Oncology. I F Tannock, R P Hill Eds. New York. McGraw-Hill 1992; 154-177.
47. Mankoff D A, Shields A F, Krohn K A. PET imaging of cellular proliferation. Radiol Clin North Am 2004 (in press).
48. Cleaver J E. Thymidine metabolism and cell kinetics. Frontiers Biol 1967: 6; 43-100.
49. Grierson J R, Shields A F. Radiosynthesis of 3′-deoxy-3′- [(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 2000: 27; 143-156.
50. Smyczek-Gargya B, Fersis N, Dittmann H, Vogel U, Reischl G, Machulla H J, Wallwiener D, Bares R, Dohmen B M. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2004: 31; 720-724.
51. Pio B. S, Park C K, Satyamurthy N, Czernin J, Phelps M E, Silverman D H. PET with fluoro-L-thmyidinc allows early prediction of breast cancer rresponse to chemotherapy. J Nucl Med 2003: 44; 76P.
52. Hockenbery D. Defining apoptosis. Am J Pathol 1995: 146; 16-19.
53. Blankenberg F, Ohtsuki K, Strauss H W. Dying a thousand deaths. Radionuclide imaging of apoptosis. Q J Nucl Med 1999: 43; 170-176.
54. Zijlstra S, Gunawan J, Burchert W. Synthesis and evaluation of a 18F-Iabelled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET. Appl Radiat Isot 2003: 58; 201-207.